Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: June 2007
-
By Christopher P. Singer — In a June 19, 2007 press release, NimbleGen Systems Inc. announced that it and Roche have entered into a definitive acquisition agreement. Under terms of the agreement Roche will pay $272.5 million to NimbleGen stockholders, and NimbleGen will become an integrated part of Roche Applied Science, a group…
-
By Kevin E. Noonan — While Craig Venter is trying to synthesize a "minimal genetic complement" bacteria (see "Patent Life (Really)"), a consortium of 35 research groups from 80 research centers are attacking the problem from the other end of the phylogenetic tree: what is needed (minimally) to encode a human being? Known…
-
By Baltazar Gomez — On June 14, 2007, CryoLife, Inc. of Kennesaw, Georgia announced the grant of U.S. Patent No. 7,226,615 directed to BioFoam®, a protein hydrogel foam for rapidly filling and sealing open wounds. CyroLife’s BioFoam® can be used in sports medicine for rapidly closing open wounds and allowing athletes to continue…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sanofi-Aventis U.S. LLC et. al. v. Sandoz, Inc.3:07-cv-02762; filed June 14, 2007 in the District Court of New Jersey Infringement of U.S.…
-
June 21-22, 2007 – Technology IP Due Diligence Conference (American Conference Institute) – San Francisco, CA*** June 21-22, 2007 – Pharma/Biotech Patent Boot Camp (American Conference Institute) – New York, NY*** June 26-28, 2007 – Euro-Biotech Forum 2007 – Paris, France June 28, 2007 – "Patent Licensing Post MedImmune: Proceed with Caution: Best Practices for…
-
By Kevin E. Noonan — More important (and perhaps even more sought after) than the alchemist’s Philosopher’s Stone have been the efforts over the past several years to find a substitute for embryonic stem (ES) cells. In view of ethical considerations and the Bush Administration’s religion-based (and politically-motivated) restrictions on federal funding for…
-
By Christopher P. Singer — As previously reported on Patent Docs, the biotechnology, chemical, and pharmaceuticals technology groups at the U.S. Patent Office held their quarterly customer partnership meeting on June 13, 2007. While the stated purpose of the meeting was merely to encourage dialog between practitioners, patent applicants, and the Office (i.e.,…
-
By Donald Zuhn — On Monday, the U.S. Supreme Court denied a motion to expedite consideration of a petition for a writ of certiorari filed by Pfizer Inc. in Pfizer Inc. v. Apotex, Inc. (2007). The Chief Justice took no part in the consideration or decision of Pfizer’s motion. As previously reported by…
-
By Donald Zuhn — As recently reported on Patent Docs, the Senate Judiciary Committee conducted a hearing last week on patent reform. According to reports earlier today (June 12, 2007) at internetnews.com and InfoWorld, five Republican members of the Senate Judiciary Committee are now seeking to delay the Senate bill’s progress, saying the…
-
By Donald Zuhn — Merrimack Pharmaceuticals, Inc. announced today (June 12, 2007) that it had been granted U.S. Patent No. 7,208,576. The ‘576 patent, which relates to non-glycosylated human alpha-fetoprotein (huAFP) and biologically-active fragments of non-glycosylated huAFP, is the third U.S. patent to be awarded to the Cambridge, Massachusetts-based biotech company. According to…
Patent Docs 